Wensheng Li
Research Subjects
Wensheng Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed B. M. Mehany
Zoology Department, Faculty of Science, Al-Azhar University, Cairo 11884, Egypt
1 shared publication - Dareen A. Jaiash
Pharmaceutical Chemistry Department, College of Pharmacy, Taif University, Taif 21974, Saudi Arabia
1 shared publication Eman Y. Santali
Pharmaceutical Chemistry Department, College of Pharmacy, Taif University, Taif 21974, Saudi Arabia
1 shared publication- Haiyan Li
Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
1 shared publication Hazem A. Mahdy
Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt
1 shared publication- Ibrahim. H. Eissa
Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo11884, Egypt
1 shared publication
Latest Publications
- Open Access
- 8 June 2020
- Published by Wiley in Journal of Chemistry
- Vol. 2020, 1-19
Screening of Some Sulfonamide and Sulfonylurea Derivatives as Anti-Alzheimer’s Agents Targeting BACE1 and PPARγ
In the last few decades, Alzheimer’s disease (AD) has emerged as a serious global problem, and it has been considered as the most common type of dementia. PPARγ and beta-secretase 1 (BACE1) are considered as potential targets for Alzheimer’s disease management. In the same time, sulfonylureas and sulfonamides have been confirmed to have PPARγ agonistic activity. Aiming to obtain new anti-AD agents, thirty-five compounds of sulfonamide and sulfonylurea derivatives having the same essential pharmacophoric features of the reported PPARγ agonists have been subjected to virtual screening. Docking studies revealed that five compounds (1, 2, 3, 4, and 5) have promising affinities to PPARγ. They were also docked into the binding site of BACE1. In addition, ADMET and physicochemical properties of these compounds were considered. Additionally, these compounds were further evaluated against BACE1 and PPARγ. Compound 2 showed IC50 value of 1.64 μM against BACE1 and EC50 value of 0.289 μM against PPARγ.
- 8 June 2020
- Published by Wiley in Journal of Chemistry
- Vol. 2020, 1-19
Open AccessScreening of Some Sulfonamide and Sulfonylurea Derivatives as Anti-Alzheimer’s Agents Targeting BACE1 and PPARγ
In the last few decades, Alzheimer’s disease (AD) has emerged as a serious global problem, and it has been considered as the most common type of dementia. PPARγ and beta-secretase 1 (BACE1) are considered as potential targets for Alzheimer’s disease management. In the same time, sulfonylureas and sulfonamides have been confirmed to have PPARγ agonistic activity. Aiming to obtain new anti-AD agents, thirty-five compounds of sulfonamide and sulfonylurea derivatives having the same essential pharmacophoric features of the reported PPARγ agonists have been subjected to virtual screening. Docking studies revealed that five compounds (1, 2, 3, 4, and 5) have promising affinities to PPARγ. They were also docked into the binding site of BACE1. In addition, ADMET and physicochemical properties of these compounds were considered. Additionally, these compounds were further evaluated against BACE1 and PPARγ. Compound 2 showed IC50 value of 1.64 μM against BACE1 and EC50 value of 0.289 μM against PPARγ.